Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immatics N.V. - Ordinary Shares (NQ:IMTX)

11.62 +0.27 (+2.38%)
Streaming Delayed Price Updated: 10:15 AM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immatics N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
From Bristol Myers Squibb
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Immatics: Q2 Earnings Insights ↗
Shares of Immatics (NASDAQ:IMTX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 21.62% year over year to ($0.45), which... 
Via Benzinga
News headline image
Immatics Initiates Phase 1 Clinical Trial of IMA401 in Advanced Solid Tumors ↗
Immatics N.V. (NASDAQ: IMTX) announced the initiation of a Phase 1 clinical trial of its drug candidate IMA401 for patients with recurrent and/or refractory solid tumors. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
On Tuesday, 88 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Credit Suisse Group (NYSE:CS) was the largest, in terms of market cap... 
Via Benzinga
News headline image
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
From Bristol Myers Squibb
Via Business Wire
News headline image
Immatics Unveils Early-Stage Data Of TCR-Engineered Cell Therapy In Solid Tumors ↗
Immatics N.V. (NASDAQ: IMTX) announced an interim clinical data update from its TCR-engineered cell therapy (TCR-T) approach ACTengine IMA203 targeting PRAME.... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers SCWorx (NASDAQ:WORX) shares rose... 
Via Benzinga
News headline image
BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions ↗
Switzerland-based BioCopy AG has collaborated with Immatics N.V. (NASDAQ: IMTX) to characterize T cell receptors (TCRs). T cell receptors and... 
Via Benzinga
News headline image
14 Biotech Stocks To Watch Over The Next 6 Months ↗
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Obalon Therapeutics (NASDAQ:OBLN)... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.